U.S. allows increased Vyvanse production to help ADHD drug shortage

The DEA has permitted a 24% increase in the production of ADHD drug Vyvanse to address a nationwide shortage. This move, requested by the FDA, also seeks to ensure an adequate and uninterrupted US supply of lisdexamfetamine, domestically and globally. This action anticipates a continual rise in the demand for this substance, which is a schedule II controlled substance.